STRENSIQ: New Drug Trials Snapshot Posted

A New Drug Trials Snapshot for STRENSIQ is now available. 

STRENSIQ is a drug that treats perinatal/infantile-, and

juvenile-onset hypophosphatasia, referred to as HPP. HPP is a rare, genetic,

progressive, metabolic disease in which patients experience devastating effects 

on multiple systems in the body, leading to severe disability and

life-threatening complications.

Drug Trials Snapshots provide information about who participated in clinical trials 

that supported the FDA approval of new drugs. The information provided in these 

Snapshots also highlights whether there were any differences in the benefits and 

side effects among sex, race and age groups.

See more Drug Trial Snapshots or contact us with questions at Snapshots@fda.hhs.gov.